Cargando…
Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression
Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D(2/3) rece...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239080/ https://www.ncbi.nlm.nih.gov/pubmed/25411966 http://dx.doi.org/10.1371/journal.pone.0113612 |
_version_ | 1782345559142563840 |
---|---|
author | de Kwaasteniet, Bart P. Pinto, Chedwa Ruhé, Eric H. G. van Wingen, Guido A. Booij, Jan Denys, Damiaan |
author_facet | de Kwaasteniet, Bart P. Pinto, Chedwa Ruhé, Eric H. G. van Wingen, Guido A. Booij, Jan Denys, Damiaan |
author_sort | de Kwaasteniet, Bart P. |
collection | PubMed |
description | Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D(2/3) receptor (D2/3R) binding has not been investigated in TRD subjects. We used [(123)I]IBZM single photon emission computed tomography (SPECT) to investigate striatal D2/3R binding in TRD. We included 6 severe TRD patients, 11 severe TRD patients on antipsychotics (TRD AP group) and 15 matched healthy controls. Results showed no significant difference (p = 0.75) in striatal D2/3R availability was found between TRD patients and healthy controls. In the TRD AP group D2/3R availability was significantly decreased (reflecting occupancy of D2/3Rs by antipsychotics) relative to TRD patients and healthy controls (p<0.001) but there were no differences in clinical symptoms between TRD AP and TRD patients. This preliminary study therefore does not provide evidence for large differences in D2/3 availability in severe TRD patients and suggests this TRD subgroup is not characterized by altered dopaminergic transmission. Atypical antipsychotics appear to have no clinical benefit in severe TRD patients who remain depressed, despite their strong occupancy of D2/3Rs. |
format | Online Article Text |
id | pubmed-4239080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42390802014-11-26 Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression de Kwaasteniet, Bart P. Pinto, Chedwa Ruhé, Eric H. G. van Wingen, Guido A. Booij, Jan Denys, Damiaan PLoS One Research Article Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D(2/3) receptor (D2/3R) binding has not been investigated in TRD subjects. We used [(123)I]IBZM single photon emission computed tomography (SPECT) to investigate striatal D2/3R binding in TRD. We included 6 severe TRD patients, 11 severe TRD patients on antipsychotics (TRD AP group) and 15 matched healthy controls. Results showed no significant difference (p = 0.75) in striatal D2/3R availability was found between TRD patients and healthy controls. In the TRD AP group D2/3R availability was significantly decreased (reflecting occupancy of D2/3Rs by antipsychotics) relative to TRD patients and healthy controls (p<0.001) but there were no differences in clinical symptoms between TRD AP and TRD patients. This preliminary study therefore does not provide evidence for large differences in D2/3 availability in severe TRD patients and suggests this TRD subgroup is not characterized by altered dopaminergic transmission. Atypical antipsychotics appear to have no clinical benefit in severe TRD patients who remain depressed, despite their strong occupancy of D2/3Rs. Public Library of Science 2014-11-20 /pmc/articles/PMC4239080/ /pubmed/25411966 http://dx.doi.org/10.1371/journal.pone.0113612 Text en © 2014 de Kwaasteniet et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article de Kwaasteniet, Bart P. Pinto, Chedwa Ruhé, Eric H. G. van Wingen, Guido A. Booij, Jan Denys, Damiaan Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression |
title | Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression |
title_full | Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression |
title_fullStr | Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression |
title_full_unstemmed | Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression |
title_short | Striatal Dopamine D(2/3) Receptor Availability in Treatment Resistant Depression |
title_sort | striatal dopamine d(2/3) receptor availability in treatment resistant depression |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239080/ https://www.ncbi.nlm.nih.gov/pubmed/25411966 http://dx.doi.org/10.1371/journal.pone.0113612 |
work_keys_str_mv | AT dekwaastenietbartp striataldopamined23receptoravailabilityintreatmentresistantdepression AT pintochedwa striataldopamined23receptoravailabilityintreatmentresistantdepression AT ruheerichg striataldopamined23receptoravailabilityintreatmentresistantdepression AT vanwingenguidoa striataldopamined23receptoravailabilityintreatmentresistantdepression AT booijjan striataldopamined23receptoravailabilityintreatmentresistantdepression AT denysdamiaan striataldopamined23receptoravailabilityintreatmentresistantdepression |